Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma

Original article


Afaf Abushaala, F. X . Caroli-bosc, N .Baize

Digestive Oncology Department, Hôpital de l’ Archet ii, Nice- France

JMJ Vol. 5, No 2 (Summer) 2006: 120-123


Advanced pancreatic adenocarcinoma is a rapidly fatal disease for which an active chemotherapy regimen is sought. Despite major advances in surgical procedures, radiation and chemotherapy the prognosis of this cancer remains a dismal less-than 5% survival at 5 years. At the time of diagnosis the majority of patients have locally advanced Inoperable tumours or metastatic disease. The aim of palliative chemotherapy is to improve Symptoms and survival with low toxicity.

Keywords: Advanced pancreatic adenocarcinoma, Oxaliplatin gemcitabine, Safety, Toxicity, Efficacy